Results 171 to 180 of about 21,936 (207)
Some of the next articles are maybe not open access.
Biology and Pharmacology of the Platelet P2Y12 Receptor
Current Pharmaceutical Design, 2006Platelets possess two receptors for ADP, P2Y(1) and P2Y(12). ADP is released from platelet dense granules upon platelet activation by numerous agonists and thereby amplifies platelet responses regardless of the initial stimulus. The P2Y(1) receptor is one of many platelet receptors coupled to Gq and initiates ADP-induced activation.
openaire +2 more sources
Thrombosis and Haemostasis, 2013
SummaryVerifyNow (VN) P2Y12 is a point-of-care assay used to assess response to P2Y12 inhibitors. Sodium citrate (citrate) is the standard anticoagulant used for this assay but requires a pre-incubation period. Hirudin is an alternative anticoagulant for platelet function studies that maintains physiological divalent cation levels.
Robert Storey +8 more
openaire +1 more source
SummaryVerifyNow (VN) P2Y12 is a point-of-care assay used to assess response to P2Y12 inhibitors. Sodium citrate (citrate) is the standard anticoagulant used for this assay but requires a pre-incubation period. Hirudin is an alternative anticoagulant for platelet function studies that maintains physiological divalent cation levels.
Robert Storey +8 more
openaire +1 more source
P2Y12 Is Involved in Cancer Metastasis,
Blood, 2011Abstract Abstract 3356 The platelet ADP receptor P2Y12 plays a prominent role in amplifying platelet activation, aggregation and thrombus formation, and the P2Y12 inhibitor Clopidogrel is widely used clinically to treat coronary artery, peripheral vascular and cerebrovascular diseases.
Yanhua Wang +8 more
openaire +1 more source
Blood, 2006
Abstract Affinity of platelet integrin αIIbβ3 for ligands is dynamically regulated and the activation of αIIbβ3 has been analyzed by binding assays using fibrinogen or ligand mimetic antibodies such as PAC1. Ligand binding assays are suitable for the condition when the number of receptors would reach a plateau phase before the end of ...
Masamichi Shiraga +8 more
openaire +1 more source
Abstract Affinity of platelet integrin αIIbβ3 for ligands is dynamically regulated and the activation of αIIbβ3 has been analyzed by binding assays using fibrinogen or ligand mimetic antibodies such as PAC1. Ligand binding assays are suitable for the condition when the number of receptors would reach a plateau phase before the end of ...
Masamichi Shiraga +8 more
openaire +1 more source
Arteriosclerosis, Thrombosis, and Vascular Biology, 2015
Introduction: Little is known about the role of P2Y12 oligomerization in receptor function and whether P2Y12 receptor mutations associated with human bleeding disorders may be explained by alterations in oligomerization. Objectives: 1) To determine whether P2Y12 homo- and ...
Aasma Khan +2 more
openaire +1 more source
Introduction: Little is known about the role of P2Y12 oligomerization in receptor function and whether P2Y12 receptor mutations associated with human bleeding disorders may be explained by alterations in oligomerization. Objectives: 1) To determine whether P2Y12 homo- and ...
Aasma Khan +2 more
openaire +1 more source
Potent P2Y12 Inhibitors and Bleeding Complications
Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology, 2022Ahmet, Güner +4 more
openaire +2 more sources
Platelets control liver tumor growth through P2Y12-dependent CD40L release in NAFLD
Cancer Cell, 2022Long-Jun Wu +2 more
exaly
International Expert Consensus on Switching Platelet P2Y 12 Receptor–Inhibiting Therapies
Circulation, 2017+2 more
exaly